14 January 2009 / Chief Executive’s Office
Assynt House
BeechwoodPark
Inverness, IV2 3BW
Telephone: 01463 717123
Fax: 01463 235189
Textphone users can contact us via
Typetalk: Tel 0800 959598
MEETING OF THE AREA PHARMACEUTICALCOMMITTEE
Monday 19 January2009 at 10:00
in the Board Room, Assynt House, Inverness
Video Conferencing Facilities are available.
Please contact the Board Committee Secretariat if you wish to link in.
AGENDA
1WELCOME AND APOLOGIES
2MINUTE OF MEETING OF 24 NOVEMBER 2008(attached)
The Committee is asked to approve the minute.
3MATTERS ARISING OR ONGOING
3.1Committee Membership
(a) Replacement for Alex Kelso
(b) Elections/Appointment of Office Bearers
The Committee is asked to note that elections will require to be held after 31 March 2009.
4COMMUNITY PHARMACY IMPLEMENTATION
The Committee is asked to note any updates.
5DRAFT PHARMACY ORDER 2009
The Draft Pharmacy Order 2009 and consultation document set out proposals to create a new regulator for pharmacy professionals and pharmacy premises. The closing date for comments is 9 March 2009.
The consultation can be accessed via the undernoted link:
The Committee is asked to discuss the proposals and consider the implications for Pharmacy.
6CONSULTATION ON CONTINUING PROFESSIONAL DEVELOPMENT (CPD) PROFESSIONAL STANDARDS AND GUIDANCE AND THE HANDLING OF CPD CASES
TheDepartment of Health indicated an intention to delay the preparation of statutory CPD rules under the Pharmacists and Pharmacy Technicians Order 2007, and instead include them in the rule making process for the General Pharmaceutical Council when it is established in 2010. Due to this delay, the RPSGB launched a consultation on proposals for CPD requirements based on the professional Code of Ethics.
The Committee is invitedto contribute to the RPSGB’s consultation on CPD requirements in pharmacy.
7DRAFT FRAMEWORK FOR FUTURE CLINICAL CARE DELIVERY IN NHS HIGHLAND(attached)
The Committee is asked to discuss the draft Framework.
8PALLIATIVE CARE SERVICES
At its last meeting the Committee discussed the document ‘Living and Dying Well’. A number of other documents on palliative care have been published which the Committee may also wish to consider, with a view to contributing to the development of a pharmacy strategy for palliative care services.
Copies ofthe documentsare attached/can be accessed via the undernoted links:
Living and Dying Well:
Audit Scotland Report on Palliative Care Services in Scotland:
_080821_palliative_care.pdf
Proposed Palliative Care Bill – Rosanna Cunningham (attached)
Proposed Bill – End of Life Choices – Margo MacDonald (attached)
Consultation MLX 356 Mixing of Medicines in Palliative Care (attached)
Direct Enhanced GP Service Palliative Care (attached for information)
The Committee is asked to discuss.
9TRANSMISSION BASED PRECAUTIONS (SOURCE ISOLATION) -
DRAFT POLICY FOR CONSULTATION (previously circulated)
The Committee is asked to discuss the draft Policy.
10APPLICATIONS FOR INCLUSION IN THE PHARMACEUTICAL LIST
10.1Application by A Horsburghfor premises at 12 High Street, CononBridge (previously circulated)
To note that a response has been sent on behalf of the APC advising that it considers the current pharmaceutical care provision to be adequate.
10.2Application by D Bolger for premises at VictoriaBuildings, Main Street, Drumnadrochit
APharmacy Practices Committeehearing will take place on 27/01/09to which the APC is invited to send a representative.
10.3Application by Assura Pharmacy for premises at Units 2&3, Cradlehall Shopping Centre, Cradlehall Court, Inverness
A Pharmacy Practices Committee hearing is being reconvened to hear this application on24/02/09. A representative of the APC is invited to attend.
11REPORTS
(a) / Area Drug and Therapeutics Committee(b) / Area Clinical Forum
(c) / Tobacco Strategy Implementation Group
(d) / Coronary Heart Disease Managed Clinical Network
(e) / Consultant in Pharmaceutical Public Health
(f) / Director of Pharmacy NHS Highland
(g) / Head of Community Pharmaceutical Services NHS Highland
(h) / Head of Specialist Pharmaceutical Services
(i) / Non-Medical Prescribers Steering Group
(j) / eHealth Steering Group
(k) / Stroke Clinical Network
(l) / Diabetes Managed Clinical Network
(m) / Diabetes Managed Clinical Network – Education and Training
(n) / Drugs Misuse Service
The Committee is asked to note the reports.
12COMMUNICATIONS RECEIVED
(a) / NHS Circulars (attached):- PCA(P)(2008)23: Influenza Immunisation 2009-10: Vaccine Supply Arrangements
- PCA(P)(2008)25: National Health Service (Discipline Committees) (Scotland) Regulations 2006
(b) / Drug Alerts (attached):
- EL)08)A/17: Boehringer Ingelheim Ltd - Oramorph Oral Solution 10mg/5ml
- EL(08)A/18: Sanofi-aventis - Priadel 400mg Prolonged Release Tablets
- EL(08)A/20: Merck Serono UK – Gonal-F 900 IU/1.5ml solution for injection in a pre-filled open
- EL(08)A/21: Genus Pharmaceuticals Ltd – Tensipine MR 10mg tablets
The Committee is asked to note the communicationsreceived.
13AOCB
13.1Scottish Medicines Consortium (SMC) Review of Membership 2009 (attached)
Nominations are being invited to fill a number of membership vacancies on the SMC
and its New Drugs Committee with effect from April 2009
The Committee is asked to consider nominations.
14DATE OF NEXT MEETING
The next meeting will be held onMonday,23 March2009 at 10:00 in the Board Room, JohnDewarBuilding,Inverness.